The estimated Net Worth of Robert Rosen is at least $469 Tysiąc dollars as of 29 June 2018. Mr. Rosen owns over 225,000 units of Odonate Therapeutics Inc stock worth over $109,952 and over the last 10 years he sold ODT stock worth over $0. In addition, he makes $359,388 as Director at Odonate Therapeutics Inc.
Sign up
Mr. Rosen ODT stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Odonate Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 225,000 units of ODT stock worth $1,620,000 on 29 June 2018.
The largest trade he's ever made was exercising 225,000 units of Odonate Therapeutics Inc stock on 29 June 2018 worth over $1,620,000. On average, Robert trades about 22,826 units every 35 days since 2014. As of 29 June 2018 he still owns at least 98,171 units of Odonate Therapeutics Inc stock.
You can see the complete history of Mr. Rosen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Rosen biography
Robert Harvey Rosen serves as Director of the Company. Rosen has served as a director since July 2017. From 2013 to February 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc. and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. From 2014 to 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, he served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University. The Board has concluded that Mr. Rosen should serve as a director based on his leadership experience in the biotechnology and pharmaceutical industries and expertise in commercializing pharmaceutical products.
What is the salary of Robert Rosen?
As the Director of Odonate Therapeutics Inc, the total compensation of Robert Rosen at Odonate Therapeutics Inc is $359,388. There are 4 executives at Odonate Therapeutics Inc getting paid more, with Joseph O'Connell having the highest compensation of $1,980,570.
How old is Robert Rosen?
Robert Rosen is 64, he's been the Director of Odonate Therapeutics Inc since 2017. There are 2 older and 9 younger executives at Odonate Therapeutics Inc. The oldest executive at Odonate Therapeutics Inc is Dr. Joseph P. O'Connell M.D., 66, who is the Chief Medical Officer.
What's Robert Rosen's mailing address?
Robert's mailing address filed with the SEC is C/O LA JOLLA PHARMACEUTICAL COMPANY, 201 JONES ROAD, SUITE 400, WALTHAM, MA, 02451.
Insiders trading at Odonate Therapeutics Inc
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis oraz Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
What does Odonate Therapeutics Inc do?
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
What does Odonate Therapeutics Inc's logo look like?
Complete history of Mr. Rosen stock trades at Heron Therapeutics Inc, La Jolla Pharmaceutical Co oraz Odonate Therapeutics Inc
Odonate Therapeutics Inc executives and stock owners
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joseph O'Connell,
Chief Medical Officer -
John Lemkey,
Chief Operating Officer -
Dr. Joseph P. O'Connell M.D.,
Chief Medical Officer -
Craig Johnson,
Independent Director -
Laura Douglass,
Independent Director -
Robert Rosen,
Director -
Kevin Tang,
Chairman of the Board, Chief Executive Officer -
Aaron Davis,
Independent Director -
Michael Hearne,
Chief Financial Officer -
Kim Ma,
Sr. VP of Clinical Operations -
Jennifer Schroeder,
Sr. VP of Program Management & Technology -
Tracey McKennon,
Sr. VP of Quality Assurance -
Stewart M. Kroll,
Chief Devel. Officer -
Thomas Wei,
Chief Scientific Officer -
Dr. Steven S. Pfeiffer Ph.D.,
Sr. VP of Technical Operations -
Ryan Cole,
Sr. VP of Operations -
Jeff L Vacirca,
Director -
Capital, Llc Boxer Asset Ma...,
-
George F Tidmarsh,
Director -
Robert D Millham,
Chief Operating Officer -
John G Lemkey,
Chief Operating Officer -
Laura L. Johnson,
Director -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Operating OfficerChief Financial Officer -
Capital, Llc Boxer,
10% owner -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Financial Officer -
Capital, Llc Eco R1,
10% owner